Salford Lung Study results achieve superior reduction in exacerbations
GlaxoSmithKline and Innoviva announced positive results from the Salford Lung Study in COPD. The study showed Relvar® Ellipta® 100/25mcg (fluticasone furoate 'FF'/vilanterol 'VI' or 'FF/VI', known as Breo® Ellipta® in the U.S.) achieved a superior reduction in exacerbations versus usual care. May 24, 2016